Abbott Laboratories posted decent Q1 2026 numbers, but a massive $21 billion cancer-testing acquisition has Wall Street spooked by immediate EPS dilution and muddy comparability metrics.

In ~10 minutes:

• Why 3-to-9 month colonoscopy wait times justify the Exact Sciences buyout.

• Abbott’s rare corporate decision to cut adult nutrition prices to revive volume.

• Supply chain war rooms buffering local inventory to bypass Middle East shipping.

• The exact accounting shift that instantly blurred legacy growth numbers.

Abbott’s medical device core, anchored by a 13.2% growth rate, remains an absolute machine. Yet the decision to embed Exact Sciences immediately into "comparable sales" left analysts questioning whether it masks a softening organic diagnostic base, prompting a nearly 5% earnings-day drop. 📉 We unpack the financial optics versus the strategic reality of buying healthcare plumbing.

Company: Abbott Laboratories (ABT) | Q1 FY2026

AI-assisted production. Feedback/ticker requests: https://x.com/EarnUnscripted.